191 related articles for article (PubMed ID: 37910181)
1. [New treatment strategies for primary lymphoma of the central nervous system].
Seidel S; Kaulen L; von Baumgarten L
Nervenarzt; 2024 Feb; 95(2):117-124. PubMed ID: 37910181
[TBL] [Abstract][Full Text] [Related]
2. Treatment of Primary Central Nervous System Lymphoma: From Chemotherapy to Small Molecules.
Mendez JS; Grommes C
Am Soc Clin Oncol Educ Book; 2018 May; 38():604-615. PubMed ID: 30231317
[TBL] [Abstract][Full Text] [Related]
3. Primary central nervous system lymphoma.
Schaff LR; Grommes C
Blood; 2022 Sep; 140(9):971-979. PubMed ID: 34699590
[TBL] [Abstract][Full Text] [Related]
4. Diffuse large B-cell lymphoma involving the central nervous system: biologic rationale for targeted therapy.
Roschewski M; Hodson DJ
Haematologica; 2024 Feb; 109(2):388-400. PubMed ID: 37706315
[TBL] [Abstract][Full Text] [Related]
5. [Molecular pathogenesis and therapeutic development of primary central nervous system lymphoma: update and future perspectives].
Nagane M
Rinsho Ketsueki; 2022; 63(9):1145-1156. PubMed ID: 36198540
[TBL] [Abstract][Full Text] [Related]
6. Novel agents for primary central nervous system lymphoma: evidence and perspectives.
Illerhaus G; Schorb E; Kasenda B
Blood; 2018 Aug; 132(7):681-688. PubMed ID: 29986908
[TBL] [Abstract][Full Text] [Related]
7. High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma--a randomized phase III trial (MATRix).
Schorb E; Finke J; Ferreri AJ; Ihorst G; Mikesch K; Kasenda B; Fritsch K; Fricker H; Burger E; Grishina O; Valk E; Zucca E; Illerhaus G
BMC Cancer; 2016 Apr; 16():282. PubMed ID: 27098429
[TBL] [Abstract][Full Text] [Related]
8. [New Advances in the Treatment of Primary Central Nervous System Lymphoma--Review].
Hu BN; Yang X; Yuan YP; Chen YJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Apr; 29(2):633-637. PubMed ID: 33812443
[TBL] [Abstract][Full Text] [Related]
9. Lymphomas of Central Nervous System.
Yokogami K; Azuma M; Takeshima H; Hirai T
Adv Exp Med Biol; 2023; 1405():527-543. PubMed ID: 37452952
[TBL] [Abstract][Full Text] [Related]
10. Patterns of relapse after successful completion of initial therapy in primary central nervous system lymphoma: a case series.
Patel MP; Kirkpatrick JP; Johnson MO; Healy P; Herndon JE; Lipp ES; Miller ES; Desjardins A; Randazzo D; Friedman HS; Ashley DM; Peters KB
J Neurooncol; 2020 Apr; 147(2):477-483. PubMed ID: 32140975
[TBL] [Abstract][Full Text] [Related]
11. Advances and challenges in the treatment of primary central nervous system lymphoma.
Yang H; Xun Y; Yang A; Liu F; You H
J Cell Physiol; 2020 Dec; 235(12):9143-9165. PubMed ID: 32420657
[TBL] [Abstract][Full Text] [Related]
12. Central Nervous System Lymphomas.
Grommes C
Continuum (Minneap Minn); 2020 Dec; 26(6):1476-1494. PubMed ID: 33273169
[TBL] [Abstract][Full Text] [Related]
13. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
[TBL] [Abstract][Full Text] [Related]
14. Treatment Options for Recurrent Primary CNS Lymphoma.
Kaulen LD; Baehring JM
Curr Treat Options Oncol; 2022 Nov; 23(11):1548-1565. PubMed ID: 36205806
[TBL] [Abstract][Full Text] [Related]
15. Analysis of Key Factors Associated with Response to Salvage High-Dose Methotrexate Rechallenge in Primary Central Nervous System Lymphoma with First Relapse.
Du P; Chen H; Shen L; Liu X; Wu X; Chen L; Cao A; Geng D
Curr Oncol; 2022 Sep; 29(9):6642-6656. PubMed ID: 36135091
[TBL] [Abstract][Full Text] [Related]
16. Evolution of the treatment of primary central nervous system lymphoma in a Regional Cancer Center of South India: Impact of high-dose methotrexate on treatment outcome.
Rudresha AH; Chaudhuri T; Lakshmaiah KC; Babu G; Lokesh KN; Rajeev LK
J Cancer Res Ther; 2020; 16(1):13-17. PubMed ID: 32362603
[TBL] [Abstract][Full Text] [Related]
17. Primary central nervous system lymphoma: Novel precision therapies.
Mondello P; Mian M; Bertoni F
Crit Rev Oncol Hematol; 2019 Sep; 141():139-145. PubMed ID: 31295667
[TBL] [Abstract][Full Text] [Related]
18. Challenges in the management of primary central nervous system lymphoma.
Sun X; Lv L; Wu Y; Cui Q; Sun S; Ji N; Liu Y
Crit Rev Oncol Hematol; 2023 Aug; 188():104042. PubMed ID: 37277008
[TBL] [Abstract][Full Text] [Related]
19. Primary Central Nervous System Lymphomas.
Chukwueke U; Grommes C; Nayak L
Hematol Oncol Clin North Am; 2022 Feb; 36(1):147-159. PubMed ID: 34801161
[TBL] [Abstract][Full Text] [Related]
20. Long-term Complete Remission of Decitabine-Primed Tandem CD19/CD22 CAR-T Therapy with PD-1 and BTK Inhibitors Maintenance in a Refractory Primary Central Nervous System Lymphoma Patient.
Zou R; Zhou X; Liu H; Wang P; Xia F; Kang L; Yu L; Wu D; Jin Z; Qu C
Cancer Res Treat; 2023 Oct; 55(4):1363-1368. PubMed ID: 37321275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
